Plan de Cuques Saint Avertin ,
Saint Gemmes sur Loire; Thevenet P., md, Saint Malo ,
Irritable bowel syndrome: A technical review for practice guideline development, Gastroenterology, vol.112, issue.6, pp.2120-2157, 1997. ,
DOI : 10.1053/gast.1997.v112.agast972120
Treatment of irritable bowel syndrome: a review of randomised controlled trials, Gut, vol.48, issue.2, pp.272-82, 2001. ,
DOI : 10.1136/gut.48.2.272
Pharmacologic Treatment of the Irritable Bowel Syndrome, Annals of Internal Medicine, vol.133, issue.2, pp.136-183, 2000. ,
DOI : 10.7326/0003-4819-133-2-200007180-00013
Pharmacologic therapy for the irritable bowel syndrome, The American Journal of Gastroenterology, vol.91, issue.1, pp.750-758, 2003. ,
DOI : 10.1016/S0140-6736(02)09712-X
Patient-perceived severity of irritable bowel syndrome in relation to symptoms, health resource utilization and quality of life, Alimentary Pharmacology and Therapeutics, vol.11, issue.3, pp.553-562, 1997. ,
DOI : 10.1046/j.1365-2036.1997.00160.x
The Economic Consequences of Irritable Bowel Syndrome, Archives of Internal Medicine, vol.163, issue.8, pp.929-964, 2003. ,
DOI : 10.1001/archinte.163.8.929
Functional bowel disorders and irritable bowel syndrome in Europe, Alimentary Pharmacology and Therapeutics, vol.304, issue.s3, pp.75-84, 2003. ,
DOI : 10.1080/00365520152584770
Basic and clinical aspects of visceral hyperalgesia, Gastroenterology, vol.107, issue.1, pp.271-93, 1994. ,
DOI : 10.1016/0016-5085(94)90086-8
Nutrient tasting and signalling mechanisms in the gut. II. The intestine as a sensory organ: neural, endocrine and immune responses, Am J Physiol (Gastrointest. Liver Physiol.), vol.277, pp.922-930, 1999. ,
Critique du pouvoir couvrant intestinal et mesure de la surface spécifique, Med Chir Dig, vol.22, pp.1-3, 1993. ,
Effet de la Montmorillonite beidellitique sur la concentration de l'hydrogène expiré, Am Gastroenterol Hépatol, vol.23, pp.235-241, 1987. ,
Etude comparative de l'effet de Bedelix sur la surproduction de gaz intestinaux induite par un repas riche en hydrates de carbone fermentescibles, Med Chir Dig, vol.23, pp.442-446, 1994. ,
The Functional Gastrointestinal Disorders: Diagnosis, Pathophysiology and Treatment, 1994. ,
Validation of a French-language version of the MOS 36-Item Short Form Health Survey (SF-36) in young healthy adults, Journal of Clinical Epidemiology, vol.48, issue.8, pp.1051-60, 1995. ,
DOI : 10.1016/0895-4356(94)00227-H
Clinical trial guidelines for pharmacological treatment of irritable bowel syndrome, Alimentary Pharmacology and Therapeutics, vol.45, issue.5, pp.569-80, 2003. ,
DOI : 10.1046/j.1365-2796.2001.00891.x
Entry criteria for drug trials of irritable bowel syndrome, The American Journal of Medicine, vol.107, issue.5, pp.51-59, 1999. ,
DOI : 10.1016/S0002-9343(99)00079-0
Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial, The Lancet, vol.355, issue.9209, pp.1035-1075, 2000. ,
DOI : 10.1016/S0140-6736(00)02033-X
Tegaserod, Alimentary Pharmacology and Therapeutics, vol.106, issue.3, pp.277-89, 2001. ,
DOI : 10.1016/S0140-6736(00)02033-X
A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation, Alimentary Pharmacology and Therapeutics, vol.39, issue.2, pp.1877-88, 2002. ,
DOI : 10.1111/j.1572-0241.2000.02179.x
An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome, Gut, vol.52, issue.5, pp.671-677, 2003. ,
DOI : 10.1136/gut.52.5.671
Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients, Alimentary Pharmacology and Therapeutics, vol.94, issue.11, pp.1419-1446, 1999. ,
DOI : 10.1016/0014-2999(87)90475-4